Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Experts are expecting strong results driven by the continued success of Lilly's blockbuster drugs, particularly the diabetes franchise. However, there are also concerns about potential headwinds from regulatory s